QTRX Earnings Date: Nov 9, 2026 (Estimated) — Quanterix Corporation
NASDAQ · Healthcare · Medical Devices
Updated
When is QTRX's next earnings date?
Quanterix Corporation (QTRX) is expected to report Q3 2026 earnings on Monday, November 9, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.42 on revenue of $33.9M.
How did QTRX do in its last earnings report?
In its most recent report on Aug 10, 2026 (Q2 2026), Quanterix Corporation posted EPS of -$0.47 versus the -$0.41 estimate, a miss of 23.7%. Revenue was $32.9M against a $37.5M estimate. The stock's 1-day post-earnings move was -40.0%.
How much does QTRX stock move after earnings?
QTRX beat EPS estimates in 4 of its last 8 reported quarters. Over the last 7 reports the stock moved an average of 12.2% (up or down) in the day after earnings.
About Quanterix Corporation
Quanterix Corporation, based in Billerica, Massachusetts, is a life sciences enterprise dedicated to pioneering and commercializing advanced digital immunoassay platforms. These sophisticated systems are designed to enhance precision health in both scientific research and diagnostic applications, reaching markets across North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company's core offerings include several innovative instruments: The HD-X instrument, which provides highly sensitive and automated multiplex protein detection. The SR-X instrument, enabling researchers to leverage Simoa detection technology for diverse uses, such as the direct detection of nucleic acids. The SP-X instrument, which utilizes Simoa planar array technology for conducting multiplex chemiluminescent immunoassays. Alongside these platforms, Quanterix also supplies crucial consumables, including assay kits and reagents. In addition to its product line, the company delivers various contract research services, encompassing sample analysis, the development of custom "homebrew" assays, and other specialized research and development projects. Quanterix's operational focus spans critical health areas like neurology, oncology, cardiology, infectious diseases, and inflammation. Its clientele within the life science research sector primarily consists of laboratories affiliated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research organizations. Sales are managed through a multifaceted approach, combining a direct sales force, dedicated support organizations, and a network of distributors or sales agents. The company was initially incorporated in 2007 as Digital Genomics, Inc., before rebranding to Quanterix Corporation in August of the same year.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-10 | Q2 2026 | -0.41 | -0.47 | -23.68% | $32.9M | ❌ Miss | -39.95% | -35.73% | -32.26% |
| 2026-05-06 | Q1 2026 | -0.56 | -0.37 | +33.93% | $36.4M | ✅ Beat | -16.41% | -12.46% | +0.30% |
| 2026-03-02 | Q4 2025 | -0.40 | -0.47 | -17.50% | $43.9M | ❌ Miss | -7.27% | -19.43% | -44.39% |
| 2025-11-10 | Q3 2025 | -0.41 | -0.35 | +14.63% | $40.2M | ✅ Beat | -2.34% | +8.01% | +48.83% |
| 2025-03-17 | Q4 2024 | -0.22 | -0.30 | -36.36% | $35.2M | ❌ Miss | -1.79% | -1.24% | -26.37% |
| 2024-05-07 | Q1 2024 | -0.31 | -0.26 | +16.13% | $32.1M | ✅ Beat | -4.90% | -3.11% | -10.02% |
| 2024-02-29 | Q4 2023 | -0.32 | -0.33 | -3.12% | $31.5M | ❌ Miss | +12.69% | +17.07% | -0.75% |
| 2023-08-07 | Q2 2023 | -0.38 | -0.16 | +57.89% | $31.0M | ✅ Beat | — | — | — |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $61.1M total
| Segment | Share | Revenue | YoY | Q2 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Product | 38.4% | $23.5M | +39.5% | $19.9M | $20.7M | $16.8M | $26.2M |
| Consumable And Other Products | 32.4% | $19.8M | +33.2% | $17.4M | $18.1M | $14.9M | $19.0M |
| Service And Other Revenue | 14.8% | $9.0M | +27.2% | — | $8.8M | $7.1M | $14.0M |
| Instruments | 6.0% | $3.7M | +86.8% | $2.5M | $2.6M | $2.0M | $7.2M |
| Research Services | 4.9% | $3.0M | -25.7% | $10.1M | $5.6M | $4.0M | $8.0M |
| Other Services | 2.8% | $1.7M | +252.4% | $670K | $568K | $494K | $2.9M |
| License and Service | 0.7% | $412K | -22.6% | $729K | $771K | $532K | $46K |
By region
Q2 FY26 · $23.5M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| North America | 49.4% | $11.6M | +36.7% | — | $11.7M | $8.5M | $13.9M |
| EMEA | 34.1% | $8.0M | +50.7% | $19.3M | $5.2M | $5.3M | $8.1M |
| Asia Pacific | 16.4% | $3.9M | +27.6% | $7.7M | $3.8M | $3.0M | $4.1M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.